Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novartis Ag (NVS)

Novartis Ag (NVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 199,111,584
  • Shares Outstanding, K 2,291,800
  • Annual Sales, $ 53,166 M
  • Annual Income, $ 12,611 M
  • 60-Month Beta 0.59
  • Price/Sales 3.85
  • Price/Cash Flow 10.71
  • Price/Book 3.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 1.31
  • Number of Estimates 1
  • High Estimate 1.31
  • Low Estimate 1.31
  • Prior Year 1.31
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
83.97 +3.47%
on 10/02/19
87.80 -1.05%
on 09/20/19
+0.60 (+0.70%)
since 09/18/19
3-Month
83.97 +3.47%
on 10/02/19
94.87 -8.42%
on 07/19/19
-7.38 (-7.83%)
since 07/18/19
52-Week
72.19 +20.35%
on 12/27/18
95.00 -8.55%
on 07/18/19
+11.02 (+14.53%)
since 10/18/18

Most Recent Stories

More News
$30.26 Billion (Painkillers) Analgesic Drugs Market Companies are Investing in Strategic Acquisitions | The Business Research Company

Companies in the analgesics market are increasingly focusing on acquisition as a strategy for growth. Leading analgesic drug manufacturers are acquiring smaller companies to gain competitive advantage...

NVS : 86.88 (-0.40%)
Factors Setting the Tone for Novartis' (NVS) Q3 Earnings

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Novartis (NVS) reports third-quarter 2019 results.

PFE : 36.46 (unch)
MRK : 84.68 (+1.05%)
NVS : 86.88 (-0.40%)
GILD : 64.91 (-0.49%)
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD

Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.

ABBV : 76.46 (+1.76%)
NVS : 86.88 (-0.40%)
GSK : 42.53 (+0.14%)
INCY : 77.76 (+0.43%)
Roche Posts Solid Sales for First 9 Months of '19, Ups View

Roche (RHHBY) reports strong sales in the first nine months of 2019 and raises guidance.

RHHBY : 36.8100 (+0.68%)
NVS : 86.88 (-0.40%)
AMGN : 202.72 (-0.41%)
ONCE : 100.04 (-0.94%)
Topical Drug Delivery Market 2019 Industry Size, Trends, Global Growth, Insights and Forecast Research Report 2024

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include GlaxoSmithKline...

BAYRY : 18.1900 (-0.49%)
CRRTF : 0.6794 (+0.06%)
NVS : 86.88 (-0.40%)
VRX.TO : 30.80 (-3.33%)
Eyevance Pharmaceuticals Acquires TOBRADEX® ST and NATACYN®

Eyevance Pharmaceuticals, committed to developing and commercializing innovative and impactful ophthalmic products, is pleased to announce the acquisition of TOBRADEX® ST (tobramycin/dexamethasone ophthalmic...

NVS : 86.88 (-0.40%)
Ocular Drug Delivery Technology Market : Discussion Of Market Drivers, Key Vendors And Challenges With Forecast To 2024

Ocular drug delivery refers to the treatment of ophthalmic diseases. Ophthalmic diseases affect various parts of the eye anatomy, are specified on the basis of their position namely, anterior segment and...

CLSD : 0.83 (+2.37%)
NVS : 86.88 (-0.40%)
PFE : 36.46 (unch)
VRX.TO : 30.80 (-3.33%)
Numab Appoints Daniel Vasella to Board of Directors

Numab Therapeutics AG today announced that effective October 1 it has appointed former Novartis CEO and Chairman Dr. Daniel Vasella to its Board of Directors.

NVS : 86.88 (-0.40%)
Specialty Generic Drugs Market Size – Industry Analysis, Share, Growth, Trends, and Forecast 2026

Market Study Report, LLC's latest research report on 'Specialty Generic Drugs Market' delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market...

ENDP : 4.88 (+0.93%)
NVS : 86.88 (-0.40%)
PFE : 36.46 (unch)
VRX.TO : 30.80 (-3.33%)
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo

NVO : 52.52 (-0.30%)
PFE : 36.46 (unch)
NVS : 86.88 (-0.40%)
JNJ : 127.70 (-6.22%)
GSK : 42.53 (+0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade NVS with:

Business Summary

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on...

See More

Key Turning Points

2nd Resistance Point 87.28
1st Resistance Point 87.08
Last Price 86.88
1st Support Level 86.52
2nd Support Level 86.17

See More

52-Week High 95.00
Last Price 86.88
Fibonacci 61.8% 86.29
Fibonacci 50% 83.60
Fibonacci 38.2% 80.90
52-Week Low 72.19

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar